Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Inclusion criteria:~* Histologically, cytologically, or radiologically confirmed hepatocellular carcinoma (HCC) meeting 1 of the following criteria:~  * Localized, surgically unresectable disease~    * Candidates for radical surgery for locally advanced disease are excluded~ * Metastatic disease~* Measurable disease, defined as ≥ 1 lesion, outside of pretreated areas, that can be measured in ≥ 1 dimension as ≥ 10 mm by spiral or multi-slice CT scan or MRI~* Child-Pugh class A or mildly decompensated Child-Pugh class B liver dysfunction~Exclusion criteria:~* Clinical ascites of any grade~* Clinical symptoms or history of CNS metastases or leptomeningeal disease~* Known fibrolamellar HCC or mixed cholangiocarcinoma and HCC~PATIENT CHARACTERISTICS:~Inclusion criteria:~* WHO performance status 0-1~* Hemoglobin ≥ 9.0 g/dL~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 75,000/mm³~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* ALT ≤ 7 times ULN~* Albumin ≥ 2.5 g/dL~* Creatinine clearance ≥ 40 mL/min~* Quick test ≥ 50% (adequate coagulation)~* Urine dipstick for proteinuria \< 2+ OR ≤ 1 g of protein in 24-hour urine collection~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 12 months after completion of study therapy~Exclusion criteria:~* Pregnant or nursing~* Encephalopathy~* Malignancy within the past 5 years except for adequately treated cervical carcinoma in situ or localized nonmelanoma skin cancer~* Hemorrhagic or thrombotic cerebrovascular event in the past 12 months~* Documented variceal hemorrhage within the past 3 months~* History or presence of clinically significant acute or unstable cardiovascular, cerebrovascular, renal, gastrointestinal, pulmonary, immunological (except for the presence of hepatitis B virus, hepatitis C virus, or cirrhosis), endocrine, or central nervous system disorders~* Known HIV infection~* Active infection requiring IV antibiotics~* Arterial hypertension ≥ 150/100 mm Hg, despite therapy~* Ongoing cardiac dysrhythmias ≥ grade 2~* Atrial fibrillation of any grade~* Prolongation of QTc \> 500 msec in screening ECG or history of familial long QT syndrome~* Inability to take oral medications~* Psychiatric disorder precluding understanding of information of study-related topics, giving informed consent, or interfering with compliance for oral drug intake~PRIOR CONCURRENT THERAPY:~Inclusion criteria:~* At least 4 weeks since prior surgery or liver-directed therapy (e.g., transarterial embolization/chemoembolization \[limited to 5 treatments\], radiofrequency ablation, cryoablation, radiotherapy, or percutaneous ethanol injection)~  * Previously treated lesions must remain separate from those to be measured in the present study~* Low-dose anticoagulants for maintenance of patency of central venous access or prevention of deep vein thrombosis allowed~Exclusion criteria:~* Prior systemic anticancer treatment for hepatocellular carcinoma~* Prior organ transplantation~* Treatment in a clinical study within the past 30 days~* Concurrent full-dose anticoagulant or requirement for anticoagulant therapy~* Concurrent experimental drugs or other anticancer therapy~* Concurrent use or anticipated need for CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, and protease inhibitors)~* Concurrent CYP3A4 inducers (e.g., carbamazepine, continuous treatment with dexamethasone \[\> 2 mg/day for \> 7 days\], phenobarbital, phenytoin, rifampicin, and St John's wort)~  * Concurrent antacids allowed provided they are administered \> 1 hour before or \> 1 hour after study drug~* Concurrent elective major surgery~* Concurrent radiotherapy~  * Concurrent analgesic radiotherapy of nontarget lesions allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous sunitinib treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete